Guggenheim initiated coverage of Nautilus Biotechnology with a Buy rating and $6 price target. The analyst says the company has an innovative platform for proteome analysis and discovery applications. The company’s platform addresses the limitations of existing protein analysis technologies with high-throughput capabilities and unique discovery use cases, the analyst tells investors in a research note. The firm believes Nautilus’ technology fills a market need for new proteome analysis tools.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
- Nautilus Biotechnology assumed with a Hold from Buy at Jefferies
- Nautilus Biotechnology’s ESG Challenge: Navigating the Rising Tide of Corporate Responsibility Standards
- Nautilus Biotechnology Reports First Quarter 2024 Financial Results
- Nautilus Biotechnology reports Q1 EPS (15c) vs (12c) last year
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue